Jean Pujals Kury, MD
Endocrinology, Diabetes & Metabolism · Bayamon, PRNPI 1134549793
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,513 of the $49,709 with a category attached, or 85.5%. Dexcom, Inc. accounts for 97.6% of it on its own, with 14 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $289.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$48K
- Medtronic$276
- Novo Nordisk$260
- Sanofi-aventis U.S. LLC$169
- Eli Lilly Export S.A. Puerto Rico Branch$109
- Amgen$98
- plus $301 from 9 others
What the payments were for
- Speaking & faculty fees$42,51386%
- Travel & lodging$3,9868%
- Food & beverage$2,9346%
- Education$2761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 117 | $48,498 |
| Medtronic | 2 | $276 |
| Novo Nordisk | 22 | $260 |
| Sanofi-aventis U.S. LLC | 3 | $169 |
| Eli Lilly Export S.A. Puerto Rico Branch | 5 | $109 |
| Amgen | 4 | $98 |
| AstraZeneca | 6 | $92 |
| Merck | 4 | $54 |
| Johnson & Johnson | 2 | $46 |
| Abbott | 2 | $32 |
| Bayer | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Bayer Puerto Rico Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
| Lilly USA, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$32,148
- DEXCOM G6 TRANSMITTER$14,780
- DEXCOM STELO GLUCOSE BIOSENSOR$9,619
How this compares
$49,709 in reported general payments places this provider in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 1,102 | $1,107,540 |
| OzempicSemaglutide | 727 | $724,665 |
| JardianceEmpagliflozin | 582 | $576,836 |
| MounjaroTirzepatide | 493 | $545,604 |
| FarxigaDapagliflozin Propanediol | 554 | $519,738 |
| JanuviaSitagliptin Phosphate | 285 | $243,823 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 209 | $212,345 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 206 | $192,962 |
| Xigduo XrDapaglifloz Propaned/Metformin | 178 | $181,843 |
| TradjentaLinagliptin | 231 | $180,078 |
| SynthroidLevothyroxine Sodium | 1,650 | $164,129 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 151 | $158,988 |
| Jentadueto XrLinagliptin/Metformin Hcl | 120 | $71,724 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 41 | $68,492 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $66,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Humalog Mix 75-25 | $7 | $1,724,1312,053 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr, Jentadueto Xr | $19 | $1,319,5031,443 claims |
| Novo NordiskOzempic | $260 | $724,665727 claims |
| AstraZenecaFarxiga | $92 | $519,738554 claims |
| MerckJanuvia, Janumet Xr, Janumet | $54 | $473,649520 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $169 | $73,522537 claims |
| AmgenProlia | $98 | $31,80918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Bayamon
- Altagracia Alcantara GonzalezBayamon$58K
- Paola Mansilla-LetelierBayamon$33K
- Angel Comulada RiveraBayamon$31K
- Gloria Vega CarattiniBayamon$26K
- Hiram Maldonado RiveraBayamon$7K
- Jose Garcia MateoPonce$945K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.